MTND2P33

Across TCGA pan-cancer cohorts, MTND2P33 RNA is linked to patient survival in 13 of 34 cancer types, making it the most broadly survival-associated MTND2P33 data layer.

The strongest signal is observed in cholangiocarcinoma (CHOL), where higher MTND2P33 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated MTND2P33 expression acts as an unfavorable survival marker, although some lineages such as LUSC and KIRP show a favorable association.

CHOL, LUSC, and UCEC are the cancer types where MTND2P33 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CHOL	OS	Tertile	All	0.019	0.800	<.001	72	view →
LUSC	DFS	Tertile	All	0.954	0.731	.004	51	view →
UCEC	DFS	Tertile	IV	0.136	0.729	<.001	48	view →
KIRP	DFS	Tertile	IV	0.765	0.042	.003	36	view →
DLBC	OS	Tertile	III,IV	0.175	0.874	.025	27	view →
SARC	OS	Tertile	All	0.501	0.871	<.001	27	view →
SKCM	OS	Tertile	III,IV	0.952	0.776	.020	24	view →
UVM	DFS	Tertile	III,IV	0.071	0.636	<.001	9	view →
READ	DFS	Tertile	IV	0.255	0.628	.020	9	view →
LIHC	DFS	Tertile	II,III,IV	0.194	0.435	.011	9	view →
KICH	OS	Tertile	All	1.000	0.806	.028	7	view →
THCA	DFS	Tertile	All	0.959	0.811	.046	3	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 13 lineages.

MTND2P33–CHOL (OS)

Open the CHOL breakdown →